ACT Brief: AI as Design Advisor, Autonomous Agent Governance, Oral Weight-Loss Therapy Switch

This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.

• In part four of her interview, Claire Riches, VP of clinical solutions at Citeline, makes the case for AI as a sophisticated strategic advisor in trial design while arguing that humans must remain in the lead. Especially when factors the model can't fully account for are at stake, human judgment becomes essential to making final decisions about what endpoints to pursue and which design trade-offs matter most.
• In a new contributed article, Tushar Sinkar examined how AI agents acquire broader autonomous capability through expanded permissions, tools, memory, and delegated authority, requiring governance focused on whether effective capability has shifted outside approved boundaries. The control problem regulated clinical research faces is no longer limited to whether a model was validated; it is whether the agent's ability to access, remember, decide, and act remains within originally assessed boundaries.
• Novo announced real-world data from the Octane study showing patients who switched from injectable weight-loss therapy to oral semaglutide lost an average of 4.1% of body weight within three months, drawn from de-identified Ro telehealth platform data representing the first real-world comparison of injectable-to-oral switching. The proportion of patients clinically classified as obese fell from 87.1% at baseline to 65.5% at three months, demonstrating that oral formulation effectiveness persists even after patients switch from injection-based therapy.

That's all for today's ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.